Fulgent Genetics Reports Strong Phase 2 Data for FID-007 in Head & Neck Cancer

summarizeSummary

Fulgent Genetics released positive interim Phase 2 data for its cancer drug FID-007, showing significantly better efficacy than current treatments for head and neck cancer, a key step in its pivot to precision medicine.

check_boxKey Events

• Positive Phase 2 Clinical Trial Results

  Interim data for FID-007 in recurrent or metastatic HNSCC showed an Objective Response Rate (ORR) of 60% and median Progression-Free Survival (mPFS) of 7.2 months.

• Significant Efficacy Over Standard of Care

  The reported ORR and mPFS are substantially higher than historical rates for standard of care (5.8-19.1% ORR, 2.3-3.7 months PFS).

• Favorable Safety Profile

  FID-007 demonstrated a favorable safety and tolerability profile, with most treatment-related adverse events being Grade 1-2.

• Upcoming ASCO Presentation

  The full abstract has been released, and the data will be presented at the ASCO 2026 Annual Meeting on June 1, 2026, with updated slides to follow.

auto_awesomeAnalysis

Fulgent Genetics announced highly encouraging interim Phase 2 clinical trial results for its drug candidate FID-007 in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The reported objective response rate (ORR) of 60% and median progression-free survival (mPFS) of 7.2 months significantly outperform historical standard of care, which typically shows ORR of 5.8-19.1% and PFS of 2.3-3.7 months. This positive data is critical for Fulgent's strategic transformation into a precision medicine company, providing a strong validation for its therapeutic development business. Investors will be watching for the full presentation at ASCO on June 1, 2026, for updated data and further insights.